Videos

Pfizer Says Court Invalidates Celebrex Patent

wochit news
|
March 12, 2014 AT 11:40 AM
Pfizer Inccorporated said a federal court has invalidated a reissue patent that would have offered an additional 18 months of U.S. exclusivity — and monopoly sales — for its blockbuster painkiller Celebrex. The U.S. Patent and Trademark Office granted Pfizer a reissue patent a year ago, covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex.